Linezolid is an antibiotic belonging to the oxazolidinone class, mainly used in the treatment of bacterial infections that are particularly resistant to other antibiotics and antimicrobials. For several years, it has been a valuable resource in the fight against antibiotic resistance, especially against Gram-positive microorganisms such as MRSA (methicillin-resistant Staphylococcus aureus) and VRE (vancomycin-resistant Enterococci).
An antibiotic with broad efficacy
Linezolid is particularly effective against a wide variety of common bacteria, including some highly resistant strains:
- Streptococci
- Enterococci
- Staphylococci
- Mycobacteria: including Mycobacterium tuberculosis
- Anaerobes: Fusobacterium, Prevotella, Porphyromonas, and Bacteroides spp, and Peptostreptococci
This drug is highly bioavailable, with over 90% absorption when taken orally, and it can also be administered intravenously.
How does Linezolid work?
The active ingredient of Linezolid is capable of inhibiting bacterial protein synthesis, thus blocking the growth of harmful organisms. The distinctive feature of this medication is that, unlike other antibiotics with a similar action, Linezolid acts on the first step of protein synthesis initiation, while other drugs target the elongation phase.
Generally, this antibiotic is not recommended for the treatment of common infections caused by microorganisms that are sensitive to penicillins or cephalosporins. Its use is advised for more complex conditions when therapeutic alternatives prove ineffective. In particular, it is used in cases of nosocomial pneumonia caused by Staphylococcus aureus, complicated skin and skin structure infections, and other similar cases.
Contraindications and side effects
On the market since 1996, Linezolid is a drug that most patients generally tolerate well; however, special attention is required for individuals with uncontrolled hypertension, thyroid disorders, carcinoid tumors, or those undergoing treatment with vasopressors, as the drug may increase sensitivity to substances with adrenergic activity.
From a pharmacological interaction standpoint, Linezolid acts as a non-selective and reversible monoamine oxidase inhibitor (MAOI). For this reason, it is contraindicated in combination with serotonergic drugs (such as SSRI, SNRI antidepressants, triptans, and some opioids) due to the risk of serotonin syndrome, a potentially serious condition.
Flarer’s role in Linezolid distribution
Flarer supports the pharmaceutical industry in the distribution of high therapeutic value active ingredients, such as Linezolid. Thanks to a consolidated network and the expertise of our consultants, we assist our partners in sourcing high-quality, traceable APIs compliant with international regulatory standards.
For more information or specific requests, our team is available for a personalized consultation.